Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer (Q36725286)

From Wikidata

Jump to navigation Jump to search

scientific article published on 10 May 2008

Language	Label	Description	Also known as
English	Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer	scientific article published on 10 May 2008

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer (English)

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

1 reference

based on heuristic

inferred from title

Toshihiko Torigoe

9

object named as

Toshihiko Torigoe

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Yoshihiko Hirohashi

12

object named as

Yoshihiko Hirohashi

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

18

object named as

Noriyuki Sato

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

13

object named as

Hiroko Asanuma

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Tetsuhiro Tsuruma

1

object named as

Tetsuhiro Tsuruma

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Tomohisa Furuhata

6

object named as

Tomohisa Furuhata

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

2

object named as

Yuji Iwayama

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Yasutoshi Kimura

8

object named as

Yasutoshi Kimura

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

5

object named as

Fumitake Hata

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Atsuhito Yagihashi

11

object named as

Atsuhito Yagihashi

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

3

object named as

Tosei Ohmura

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Tadashi Katsuramaki

4

object named as

Tadashi Katsuramaki

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Kumiko Shimozawa

14

object named as

Kumiko Shimozawa

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

17

object named as

Naohiro Nomura

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Nobuhiko Toyota

10

object named as

Nobuhiko Toyota

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

author name string

Koji Yamaguchi

7

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Minoru Okazaki

15

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Yasuhiro Mizushima

16

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Koichi Hirata

19

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

publication date

10 May 2008

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Journal of Translational Medicine

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

6

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

24

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

copyright license

Creative Commons Attribution 2.0 Generic

10 May 2008

1 reference

April 2022 Public Data File from Crossref

copyright status

1 reference

April 2022 Public Data File from Crossref

T cell immunomonitoring and tumor responses in patients immunized with a complex of cholesterol-bearing hydrophobized pullulan (CHP) and NY-ESO-1 protein.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Immunological evaluation of personalized peptide vaccination with gemcitabine for pancreatic cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

CD8+ T cells reactive to survivin antigen in patients with multiple myeloma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Inhibitors of apoptosis proteins in human cervical cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Regulators of apoptosis: suitable targets for immune therapy of cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

A potent immunogenic general cancer vaccine that targets survivin, an inhibitor of apoptosis proteins.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

A DNA vaccine targeting survivin combines apoptosis with suppression of angiogenesis in lung tumor eradication

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Phase I vaccination trial of SYT-SSX junction peptide in patients with disseminated synovial sarcoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Phase I clinical study of anti-apoptosis protein, survivin-derived peptide vaccine therapy for patients with advanced or recurrent colorectal cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Transcriptional expression of survivin and its splice variants in brain tumors in humans

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Recent advances in the development of anticancer agents targeting cell death inhibitors in the Bcl-2 protein family

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

An HLA-A24-restricted cytotoxic T lymphocyte epitope of a tumor-associated protein, survivin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

A new tumor-rejection antigen recognized by cytotoxic T lymphocytes infiltrating into a lung adenocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Identification of a gene coding for a protein possessing shared tumor epitopes capable of inducing HLA-A24-restricted cytotoxic T lymphocytes in cancer patients

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

A new era for cancer immunotherapy based on the genes that encode cancer antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Cloning of the gene coding for a shared human melanoma antigen recognized by autologous T cells infiltrating into tumor

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

30 September 2017

Tumor antigens recognized by T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

28 June 2018

Breast cancer 2004: Progress and promise on the clinical front

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

5 September 2018

HLA-A24 and survivin: possibilities in therapeutic vaccination against cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

5 September 2018

Complete remission of liver metastasis of pancreatic cancer under vaccination with a HLA-A2 restricted peptide derived from the universal tumor antigen survivin

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

5 September 2018

Tumor specific expression of survivin-2B in lung cancer as a novel target of immunotherapy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

5 September 2018

Identification of a survivin-derived peptide that induces HLA-A*0201-restricted antileukemia cytotoxic T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

5 September 2018

Identification of novel survivin-derived CTL epitopes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

5 September 2018

Cancer survival in Sweden 1960-1998--developments across four decades

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

5 September 2018

Distinct in vivo expression patterns of survivin splice variants in renal cell carcinomas

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

5 September 2018

Intradermal ras peptide vaccination with granulocyte-macrophage colony-stimulating factor as adjuvant: Clinical and immunological responses in patients with pancreatic adenocarcinoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2430193

5 September 2018

Hsp70-like protein 1 fusion protein enhances induction of carcinoembryonic antigen-specific CD8+ CTL response by dendritic cell vaccine

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Immunotherapy of patients with hormone-refractory prostate carcinoma pre-treated with interferon-gamma and vaccinated with autologous PSA-peptide loaded dendritic cells--a pilot study

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vaccination of hormone-refractory prostate cancer patients with peptide cocktail-loaded dendritic cells: results of a phase I clinical trial

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identification of a cytotoxic T lymphocyte response to the apoptosis inhibitor protein survivin in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Expression of survivin and its splice variants in gastric cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

HLA-B35-restricted immune responses against survivin in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Time trends of breast cancer survival in Europe in relation to incidence and mortality

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Association of p53 gene alterations with the expression of antiapoptotic survivin splice variants in breast cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Transcriptional expression of survivin and its splice variants in cervical carcinomas

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Spontaneous cytotoxic T-cell responses against survivin-derived MHC class I-restricted T-cell epitopes in situ as well as ex vivo in cancer patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/18471305

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1186/1479-5876-6-24

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

Dimensions Publication ID

0 references

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

15 August 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q36725286&oldid=2199236401"